Risk assessment in haematopoietic stem cell transplantation

Best Practice and Research: Clinical Haematology

Volumn 20, Issue 2, 2007, Pages 119-124

  Gratwohl, Alois ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB;

ALGORITHM; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER RELAPSE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; DISEASE CONTROL; DISEASE SEVERITY; DOCTOR PATIENT RELATION; DONOR; EDITORIAL; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL; HIGH RISK PATIENT; HISTOCOMPATIBILITY; HUMAN; LONG TERM CARE; MEDICAL DECISION MAKING; MORBIDITY; MORTALITY; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; PROGNOSIS; REDUCED INTENSITY CONDITIONING; RISK ASSESSMENT; TREATMENT INDICATION; UMBILICAL CORD BLOOD;

ACUTE DISEASE; ADULT; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, MYELOID; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 34247128208     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2006.10.011     Document Type: Editorial

References (9)

1. Copelan E.A. Hematopoietic stem cell transplantation. The New England Journal of Medicine 354 (2006) 1813-1826
2. Baccarani M., Saglio G., Goldman J., et al. Evolving concepts in the management of chronic myeloid leukemia. Recommendations from an expert panel on behalf of the European Leukemia Net. Blood 108 (2006) 1809-1820
3. Passweg J., Baldomero H., Chapuis B., et al., Swiss Transplant Working Group Blood and Marrow Transplantation Board. Haematopoietic stem cell transplantation in Switzerland. Report from the Swiss Transplant Working Group Blood and Marrow Transplantation (STABMT) Registry 1997-2003. Swiss Medical Weekly 136 (2006) 50-58
4. Allogeneic bone marrow transplantation for leukaemia in Europe. Report from the Working Party on Leukaemia, European Group for Bone Marrow Transplantation. Lancet 18 (1988) 1379-1382
5. Gratwohl A., Hermans J., Goldman J.M., et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 352 (1998) 1087-1092
6. Gratwohl A., Brand R., Apperley J., et al., Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 91 (2006) 513-521
7. Parimon T., Au D.H., Martin P.J., et al. A risk score for mortality after allogeneic hematopoietic cell transplantation. Annals of Internal Medicine 144 (2006) 407-414
8. Ottinger H.D., Ferencik S., Beelen D.W., et al. Hematopoietic stem cell transplantation: contrasting the outcome of transplantations from HLA-identical siblings, partially HLA-mismatched related donors, and HLA-matched unrelated donors. Blood 102 (2003) 1131-1137
9. Gratwohl A, Baldomero H, Schwendener A et al. for the Joint Accreditation Committee of the International Society for Cellular Therapy (ISCT) and the European Group for Blood and Marrow Transplantation (EBMT) (JACIE). Haematopoietic stem cell transplants for chronic myeloid leukaemia in Europe. Impact of cost considerations. Leukemia 2006, in press.